UCB to acquire Ra Pharmaceuticals in $2.1 billion deal
MLex Summary: Biopharmaceutical company UCB has agreed to acquire Cambridge, Massachusetts-based Ra Pharmaceuticals in a transaction valued at $2.1 billion.Statement follows below. ...To view the full article, register now.
Already a subscriber? Click here to view full article